Ombre, a San Francisco-based healthtech startup previously known as Quantbiome, has raised $3 million in seed funding to provide users with a means to evaluate their microbiome at home to improve their general health.
Led by PivotNorth Capital, with participation from Trail Mix Ventures, Shanda Group, Unilever Ventures, Social Starts’ fund Joyance Partners, and Unpopular Ventures, the round brings the total funding raised by the startup to $9.5 million. Tim Connors, Founder at PivotNorth Capital, referred to the firm’s participation by stating:
“Ombre has excellent unit economics with the ability to upsell test takers to probiotic subscribers. We see a significant upside as the business is relaunched with a new trademark, supply chain improvements, and demonstrated consumer demand for probiotic products.”
Ombre was founded back in 2016 under its former name with the aim to provide its users with probiotic subscriptions, as well as tailored lifestyle and diet recommendations, based on their unique microbiome. The startup has been developing its DNA sequencing process ever since its inception, which it now seeks to bring to its users to facilitate quantified self-care. Elise Contarsy, Ombre CEO, said about this approach:
“We believe the future of self-care is built around the concept of the quantified self. Every individual’s microbiome is unique, and we see ongoing consumer interest in knowing how to use their individual bioinformatics to take actions that improve their well-being.”
It is expected for the Over-the-counter probiotic supplement market to represent more than $80 billion by 2027. This is the result of more research confirming that gut biome regulation can help in the treatment of specific symptoms to improve general health. Ombre believes it is now positioned for growth and ready to disrupt the market by making it easier for millions of people to improve their health in an easy and effective manner.